Consult the medical resource doctors trust

UpToDate is one of the most respected medical information resources in the world, used by over 360,000 doctors and thousands of patients to find answers to medical questions.

  • Content written by a faculty of over 4,000 physicians from leading medical institutions
  • Unbiased: free of advertising or pharmaceutical funding
  • Evidence-based treatment recommendations
  • Continuously updated to incorporate new medical findings

Progestin-only pills (minipills) for contraception

INTRODUCTION

Progestin-only contraception is an option for women in whom an estrogen-containing contraceptive is either contraindicated or causes additional health concerns. Only one progestin-only oral contraceptive (OC) formulation is marketed in the United States: norethindrone 0.35 mg tablets (Micronor, Nor-QD, and generics). The progestin dose is substantially lower than the dose in any combination oral contraceptive. It is dispensed in packs of 28 active pills, which are taken continuously (ie, no pill free or nonhormonal pill week) [1].

Other types of progestin-only contraceptives include:

  • Progestin implants (eg, Implanon, Jadelle) (see "Implanon")
To continue reading this article you need to subscribe.

Read the rest of this article and others like it

The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use (click here) ©2009 UpToDate, Inc.
References Top
  1. Kaunitz, AM. Revisiting progestin-only OCs. Contemp OB/GYN 1997; 91.
  2. Benagiano, G, Primiero, FM. Seventy-five microgram desogestrel minipill, a new perspective in estrogen-free contraception. Ann N Y Acad Sci 2003; 997:163.
  3. Speroff, L, Darney, P. A Clinical Guide for Contraception, 4th ed, Baltimore, Williams and Wilkins, 2005.
  4. Lebech, PE, Svendsen, PA, Ostergaard, E, Koch, F. The effects of small doses of megestrol acetate on the cervical mucus. Acta Obstet Gynecol Scand 1969; 48:Suppl.
  5. Wright, SW, Fotherby, K, Fairweather, F. Effect of daily small doses of norgestrel on ovarian function. J Obstet Gynaecol Br Commonw 1970; 77:65.
  6. Trussell, J. Contraceptive failure in the United States. Contraception 2004; 70:89.
  7. Vessey, MP, Lawless, M, Yeates, D, et al. Progestogen-only oral contraception. Findings in a large prospective study with special reference to effectiveness. Br J Fam Plann 1985; 10:117.
  8. Dunson, TR, McLaurin, VL, Grubb, GS, Rosman, AW. A multicenter clinical trial of a progestin-only oral contraceptive in lactating women. Contraception 1993; 47:23.
  9. Guillebaud, J. Contraception: Your Questions Answered, 2nd ed, Churchill Livingstone, New York 1993.
  10. Simon, JA, Wysocki, S, Brandman, J, Axelsen, K. A comparison of therapy continuation rates of different hormone replacement agents: a 9-month retrospective, longitudinal analysis of pharmacy claims among new users. Menopause 2003; 10:37.
  11. Brenner, PF, Mishell, DR Jr, Stanczyk, FZ, Goebelsmann, U. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel. Am J Obstet Gynecol 1977; 129:133.
  12. Stanczyk, FZ, Brenner, PF, Mishell, DR Jr, et al. A radioimmunoassay for norethindrone (NET): Measurement of serum NET concentrations following ingestion of NET-containing oral contraceptive steroids. Contraception 1978; 18:615.
  13. Weiner, E, Victor, A, Johansson, ED. Plasma levels of d-norgestrel after oral administration. Contraception 1976; 14:563.
  14. McCann, MF, Potter, LS. Progestin-only oral contraception: A comprehensive review. Contraception 1994; 50:S1.
  15. Tayob, Y, Adams, J, Jacobs, HS, Guillebaud, J. Ultrasound demonstration of increased frequency of functional ovarian cysts in women using progestogen-only oral contraception. Br J Obstet Gynaecol 1985; 92:1003.
  16. Shoupe, D, Horenstein, J, Mishell, DR Jr, et al. Characteristics of ovarian follicular development in Norplant users. Fertil Steril 1991; 55:766.
  17. Barbosa, I, Bakos, O, Olsson, SE, et al. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 1990; 42:51.
  18. Maximizing the use of the progestin minipill. Contraceptive Technol Update 199; 20:19.
  19. Fotherby, K. The progestogen-only pill and thrombosis. Br J Fam Plann 1989; 15:83.
  20. Ball, MJ, Ashwell, E, Gillmer, MD. Progestagen-only oral contraceptives: comparison of the metabolic effects of levonorgestrel and norethisterone. Contraception 1991; 44:223.
  21. Hussain, SF. Progestogen-only pills and high blood pressure: is there an association? A literature review. Contraception 2004; 69:89.
  22. Godsland, IF, Crook, D, Simpson, R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323:1375.
  23. Winkler, UH. Blood coagulation and oral contraceptives. A critical review. Contraception 1998; 57:203.
  24. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998; 57:315.
  25. Heinemann, LA, Assmann, A, DoMinh, T, Garbe, E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999; 4:67.
  26. Gomes, MP. Arch Intern Med 2004; 164:1965.
  27. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.
  28. Kjos, SL, Peters, RK, Xiang, A, Thomas, D, et al. Contraception and the risk of type 2 diabetes in Latino women with prior gestational diabetes. JAMA 1998; 280:533.
  29. Furlong, LA. Ectopic pregnancy risk when contraception fails. A review. J Reprod Med 2002; 47:881.
  30. Caird, LE, Reid-Thomas, V, Hannan, WJ, et al. Oral progestogen-only contraception may protect against loss of bone mass in breast-feeding women. Clin Endocrinol (Oxf) 1994; 41:739.
  31. Weiderpass, E, Adami, HO, Baron, JA, Magnusson, C, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91:1131.
  32. Breast cancer and hormonal contraceptives: further results. Collaborative Group on Hormonal Factors in Breast Cancer. Contraception 1996; 54:1S.
  33. Halderman, LD, Nelson, AL. Impact of early postpartum administration of progestin-only hormonal contraceptives compared with nonhormonal contraceptives on short-term breast-feeding patterns. Am J Obstet Gynecol 2002; 186:1250.
white circle LOG IN
white circle DEMO